Deleuran M, Vestergaard C. Clinical heterogeneity and differential diagnosis of atopic dermatitis. Br J Dermatol. 2014;170(Suppl 1):2–6.
Irvine AD, Mina-Osorio P. Disease trajectories in childhood atopic dermatitis: an update and practitioner’s guide. Br J Dermatol. 2019;181:895–906.
Article CAS PubMed PubMed Central Google Scholar
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venerol suppl. 1980;92:44–7.
Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis Nat Rev Dis Primers. 2018;4:1.
Augustin M, Langenbruch A, Blome C, Gutknecht M, Werfel T, Stander S, Steinke S, Kirsten N, Silva N, Sommer R. Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation. J Eur Acad Dermatol Venereol. 2020;34:142–52.
Article CAS PubMed Google Scholar
Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123:144–51.
Brunner PM, Silverberg JI, Guttman-Yassky E, Paller AS, Kabashima K, Amagai M, Luger TA, Deleuran M, Werfel T, Eyerich K, Stingl G, Councilors of the International Eczema C. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137:18–25.
Article CAS PubMed Google Scholar
Schmidt SAJ, Mailhac A, Darvalics B, Mulick A, Deleuran MS, Sorensen HT, Riis JL, Langan SM. Association between atopic dermatitis and educational attainment in Denmark. JAMA Dermatol. 2021;157:1–9.
Article PubMed PubMed Central Google Scholar
Norreslet LB, Ebbehoj NE, EllekildeBonde JP, Thomsen SF, Agner T. The impact of atopic dermatitis on work life—a systematic review. J Eur Acad Dermatol Venereol. 2018;32:23–38.
Article CAS PubMed Google Scholar
Thyssen JP, Brenneche AW, Madsen ME, Pedersen MH, Trangbaek DJ, Vestergaard C. Societal Costs of moderate-to-severe atopic dermatitis occurring in adulthood: a Danish register-based study. Acta Derm Venereol. 2021;101:adv00538.
Nygaard U, Riis JL, Deleuran M, Vestergaard C. Attention-deficit/hyperactivity disorder in atopic dermatitis: an appraisal of the current literature. Pediatr Allergy Immunol Pulmonol. 2016;29:181–8.
Riis JL, Vestergaard C, Deleuran MS, Olsen M. Childhood atopic dermatitis and risk of attention deficit/hyperactivity disorder: a cohort study. J Allergy Clin Immunol. 2016;138(2):608–10. https://doi.org/10.1016/j.jaci.2016.01.027. Epub 2016 Mar 26.
Ronnstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. J Am Acad Dermatol. 2018;79(448–456): e430.
Chang YS, Chiang BL. Sleep disorders and atopic dermatitis: a 2-way street? J Allergy Clin Immunol. 2018;142:1033–40.
Farzanfar D, Dowlati Y, French LE, Lowes MA, Alavi A. Inflammation: a contributor to depressive comorbidity in inflammatory skin disease. Skin Pharmacol Physiol. 2018;31:246–51.
Article CAS PubMed Google Scholar
Wiis MAK, Heilskov S, Sørensen Jennifer A, Bang K, Egekvist H, Deleuran M, Thyssen JP, Thomsen SF, Vestergaard C. Self-reported stigmatisation among patients with atopic dermatitis (AD) or chronic spontaneous urticaria (CSU): a cross-sectional study. JEADV Clin Pract. 2022.
Thyssen JP, Rinnov MR, Vestergaard C. Disease mechanisms in atopic dermatitis: a review of aetiological factors. Acta Derm Venereol. 2021;101(9):adv00538. https://doi.org/10.2340/00015555-3908.
Schmitt J, Spuls PI, Thomas KS, Simpson E, Furue M, Deckert S, Dohil M, Apfelbacher C, Singh JA, Chalmers J, Williams HC, collaborators Hi. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol. 2014;134:800–7.
Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148:927–40.
Article CAS PubMed PubMed Central Google Scholar
Nygaard U, Vestergaard C, Deleuran M. Emerging treatment options in atopic dermatitis: systemic therapies. Dermatology. 2017;233:344–57.
Article CAS PubMed Google Scholar
Wollenberg A, Weidinger S, Worm M, Bieber T. Tralokinumab in atopic dermatitis. J Dtsch Dermatol Ges. 2021;19:1435–42.
Guttman-Yassky E, Blauvelt A, Eichenfield LF, Paller AS, Armstrong AW, Drew J, Gopalan R, Simpson EL. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol. 2020;156:411–20.
Article PubMed PubMed Central Google Scholar
Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab JPASG. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies. Br J Dermatol. 2022;186:642–51.
Article CAS PubMed Google Scholar
Le AM, Torres T. OX40-OX40L inhibition for the treatment of atopic dermatitis-focus on rocatinlimab and amlitelimab. Pharmaceutics. 2022;14(12):2753. https://doi.org/10.3390/pharmaceutics14122753.
Wollenberg A, Christen-Zach S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, Vestergaard C, Seneschal J, Werfel T, Cork MJ, Kunz B, Folster-Holst R, Trzeciak M, Darsow U, Szalai Z, Deleuran M, von Kobyletzki L, Barbarot S, Heratizadeh A, Gieler U, Hijnen DJ, Weidinger S, De Raeve L, Svensson A, Simon D, Stalder JF, Ring J, European Task Force on Atopic Dermatitis EETF. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34:2717–44.
Article CAS PubMed Google Scholar
Jameson JL, Longo DL. Precision medicine–personalized, problematic, and promising. N Engl J Med. 2015;372:2229–34.
Article CAS PubMed Google Scholar
Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, Humbert M, Jones P, Gibson PG, Vestbo J, Beasley R, Pavord ID. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47:410–9.
Thyssen JP, Vestergaard C, Deleuran M, de Bruin-Weller MS, Bieber T, Taieb A, Seneschal J, Cork MJ, Paul C, Flohr C, Weidinger S, Trzeciak M, Werfel T, Heratizadeh A, Barbarot S, Darsow U, Simon D, Torrelo A, Chernyshov PV, Stalder JF, Gelmetti C, Szalai Z, Svensson A, von Kobyletzki LB, De Raeve L, Folster-Holst R, Cristen-Zaech S, Hijnen D, Gieler U, Ring J, Wollenberg A. European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. J Eur Acad Dermatol Venereol. 2020;34:e839–42.
Article CAS PubMed Google Scholar
Charman C, Chambers C, Williams H. Measuring atopic dermatitis severity in randomized controlled clinical trials: what exactly are we measuring? J Invest Dermatol. 2003;120:932–41.
Article CAS PubMed Google Scholar
Spuls PI, Gerbens LAA, Simpson E, Apfelbacher CJ, Chalmers JR, Thomas KS, Prinsen CAC, von Kobyletzki LB, Singh JA, Williams HC, Schmitt J, collaborators Hi. Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. Br J Dermatol. 2017;176:979–84.
Article CAS PubMed Google Scholar
Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbe A, Nelson L, Clark M, Williams N, Chen Z, Ardeleanu M, Akinlade B, Graham NMH, Pirozzi G, Staudinger H, Plaum S, Radin A, Gadkari A. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181:761–9.
Article CAS PubMed PubMed Central Google Scholar
Apfelbacher CJ, Heinl D, Prinsen CA, Deckert S, Chalmers J, Ofenloch R, Humphreys R, Sach T, Chamlin S, Schmitt J. Measurement properties of adult quality-of-life measurement instruments for eczema: protocol for a systematic review. Syst Rev. 2015;4:48.
Article PubMed PubMed Central Google Scholar
Heinl D, Prinsen CAC, Sach T, Drucker AM, Ofenloch R, Flohr C, Apfelbacher C. Measurement properties of quality-of-life measurement instruments for infants, children and adolescents with eczema: a systematic review. Br J Dermatol. 2017;176:878–89.
Article CAS PubMed Google Scholar
Howells LM, Chalmers JR, Gran S, Ahmed A, Apfelbacher C, Burton T, Howie L, Lawton S, Ridd MJ, Rogers NK, Sears AV, Spuls P, von Kobyletzki L, Thomas KS. Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (RECAP). Br J Dermatol. 2020;183:524–36.
Article CAS PubMed PubMed Central Google Scholar
Pariser DM, Simpson EL, Gadkari A, Bieber T, Margolis DJ, Brown M, Nelson L, Mahajan P, Reaney M, Guillemin I, Mallya UG, Eckert L. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin. 2020;36:367–76.
van Vollenhoven R. Treat-to-target in rheumatoid arthritis - are we there yet? Nat Rev Rheumatol. 2019;15:180–6.
Iannone M, Tonini G, Janowska A, Dini V, Romanelli M. Definition of treatment goals in terms of clinician-reported disease severity and patient-reported outcomes in moderate-to-severe adult atopic dermatitis: a systematic review. Curr Med Res Opin. 2021;37:1295–301.
Article CAS PubMed Google Scholar
De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, Hercogova J, Hong CH, Katoh N, Pink AE, Richard MA, Shumack S, Silvestre JF, Weidinger S. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021;101:adv00402.
Comments (0)